An observational study in Intensive Care Medicine, Respiratory Distress Syndrome (RDS) and Sedation and Analgesia, sponsored by Guy's and St Thomas' NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-05-08.
Sponsored by Guy's and St Thomas' NHS Foundation Trust · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies in Respiratory Distress Syndrome with a site in United Kingdom — 10 open to participants now, 13 under way, 3 of them phase 3. Respiratory Distress Syndrome · United Kingdom.
Among the 47 studies in Respiratory Distress Syndrome with a site in United Kingdom, this one is the 9th largest by planned enrollment of the 15 observational ones that give a count, is one of 3 that started in 2025, is one of 16 observational ones, reaches primary completion later than 6 of the 12 other live ones, and was the 45th registered.
1,388 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.
Browse Respiratory Distress Syndrome studies →10 of the 47 studies in Respiratory Distress Syndrome with a site in United Kingdom are open now. Recruiting first, the newest first:
Aerogen Pharma Limited · Sites in United Kingdom, United States, Canada
Ages 1 hrs–24 hrs
BioAegis Therapeutics Inc. · Sites in United Kingdom, United States, Belgium and 10 more countries
Ages 18+
King's College Hospital NHS Trust · Sites in United Kingdom
Ages 34 wk–38 wk
Guy's and St Thomas' NHS Foundation Trust · Sites in United Kingdom
Ages 17+
AstraZeneca · Sites in United Kingdom, United States, Argentina and 36 more countries
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 9 · Phase 3 8 · Phase 4 2
First in 2003; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 100 across 476 observational studies indexed under Respiratory Distress Syndrome.
Median enrollment 90 across the 31 interventional studies, 132 across the 15 observational. Of the 27 that completed or were terminated, 6 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 47 have an industry lead sponsor. The 10 most frequent:
Guy's and St Thomas' NHS Foundation Trust is the lead sponsor of 295 studies on the registry; 80 are open to participants now.
Guy's and St Thomas' NHS Foundation Trust has 5 studies filed under Respiratory Distress Syndrome — fewer than ten, so there is no comparison to draw.
8 of the studies in Respiratory Distress Syndrome with a site in United Kingdom that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06776783Phase 3Aerogen Pharma LimitedSafety and Efficacy of APC-0101 in Preterm Infants With Respiratory Distress Syndrome | 2027-05 |
| NCT06014138Phase 3Guy's and St Thomas' NHS Foundation TrustVolatile Sedation for Patients With the Acute Respiratory Distress Syndrome | 2027-07-31 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT05388708University of MichiganARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND) | 2027-06-30 |
| NCT07580781Guy's and St Thomas' NHS Foundation TrustFeasibility of Protocolised Analgosedation in ECMO | 2027-08-31 |
Add all 8 to your calendar (.ics) → With an account.
Among the 47 studies in Respiratory Distress Syndrome with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Sedation (painkillers and sedative drugs) treats pain, reduces suffering, and helps patients in the intensive care unit (ICU) receiving extracorporeal membrane oxygenation (ECMO) remain comfortable. ECMO is a life support machine that provides oxygen and removes waste gases (carbon dioxide) in very sick patients with severe heart or lung failure. About 300-400 patients per year receive ECMO in the UK. These patients are younger and generally more healthy compared to other critically ill patients. However patients that survive ECMO have long-term health problems. These include anxiety, memory problems, withdrawal from medicines, and mobility issues. These problems issues could all be related to the type and amount of sedation given.
A sedation protocol is a way of guiding healthcare professionals how much sedation is given to patients in ICU. Too much sedation can cause confusion, hallucinations, excessive sleepiness, and longer time in hospital. Too little sedation can cause pain, distress, and also a longer time in hospital. Using a sedation protocol in non-ECMO patients has been shown to reduce these complications.
However, there are no protocols for giving sedation to ECMO patients in research papers. The investigators know healthcare staff find it difficult to manage sedation, and higher amounts of sedation is given to ECMO patients.
Aims:
Design/methods:
Study 1:
The investigators will study how sedation is used in adult ECMO patients and compare with non-ECMO but critically ill patients in the UK. The investigators will collect information on drug doses and pain and sedation scores. The investigators will also ask ECMO centres if they use a sedation protocol to adjust sedation doses. This information will be helpful for the design of the protocol in study 2.
Study 2:
The investigators will design a sedation protocol with input from patients, family, and staff. The investigators will organise meetings to share experiences and agree on what to include in the protocol that is considered acceptable and safe. The investigators will then assess if the protocol is safe and acceptable with staff outside the co-design group.
Patient and public involvement/engagement:
The investigators received feedback from patients and family members which helped to design this proposal, the lay summary and what to measure in a trial. Patients and family members will continue to help with development of the sedation and trial protocol. They will advise how the investigators should review study findings, and support sharing of results to the public.
Impact/dissemination:
The investigators will share findings through social media, patient charities, research papers and conferences.
Overall Aim and purpose:
Objectives:
Stage 1
Stage 2
Study design:
Stage 1: multi-centre observational cohort study reviewing analgosedation practices in UK ECMO centres comparing ECMO to non-ECMO patients The investigators will conduct a prospective multi-centre observational cohort study enrolling UK adult ECMO centres. The investigators aim to recruit all ECMO centres to participate. The investigators are recruiting sites via a well-established national pharmacist and physician ECMO groups. Analgosedation data will be collected for all ECMO patients and a representative sample of non-ECMO ICU patients either in the same unit or another representative ICU in ECMO centres with multiple ICUs. The investigators will collect outcome data to patient discharge from ICU. The investigators will organise meetings with consultant doctors at St Thomas' and Royal Brompton Hospitals to determine clinical equipoise of using a co-designed analgosedation protocol in a feasibility cluster randomised controlled trial versus no protocol.
Data collection:
Data to be collected
Patients:
Sites will record data using a printed case report form. The direct care team will de-identify identifiable patient data before uploading it on to the electronic case report form (e-CRF). The investigators will develop a e-CRF (in collaboration with with King's College London) to collect de-identified patient demographic characteristics, analgosedation management and patient outcomes. Sites will then transfer de-identified data on to the electronic data capture system (REDCap) and lock when completed to ensure patient confidentiality. The investigators will train the direct clinical care team, clinical pharmacists and research nurses at participating sites on data collection. Data collected will include baseline characteristics (age, gender, weight, height, APACHE II score and past medical history), continuous analgosedative (opioid and/or sedative) IV infusion hourly doses (excluding bolus doses), and enteral opioid and sedatives doses during a 5-day observation period documented in the patient medical record. The investigators will also document type and numerical values of pain score, sedation scores (Richmond, Agitation and Sedation Score (RASS)), delirium presence (assessed by Confusion Assessment Method for the Intensive Care Unit, CAM-ICU) and duration during the 5-day collection period Outcome data including ICU length of stay, ECMO duration and ICU mortality will be collected.
Consultant doctors:
The investigators will collect information on the number of consultant doctors who attend the meeting to review clinical equipoise, the total number of consultant doctors employed within each service, and the number of consultant doctors who confirm clinical equipoise.
Data analysis:
Quantitative analysis:
The investigators will calculate the median (interquartile range) of daily (24 hour period) dose of each analgosedation drug. The investigators will convert all opioids (enteral and intravenous) to morphine dose equivalents; benzodiazepines (enteral and intravenous) into midazolam dose equivalents using opioid and benzodiazepine conversion tables. The investigators will calculate median daily dose by dividing the sum of all analgosedation doses received during the data collection period by the number of days of collected data. To compare analgosedation doses and patient outcomes of ECMO versus non-ECMO ICU patients, the investigators will test data for normality and use summary measures for central tendency (mean, median) and variability (standard deviation, interquartile range, minimum, maximum). The investigators will present categorical data as counts (%). Comparisons will be made using parametric t-test or non-parametric Wilcoxon rank sum test depending on data distribution. The investigators will use univariable and multivariable linear regression with a priori selected co-variates to examine the association between patient factors and analgosedation dosing including use of ECMO. Data will be analysed using R Studio.
Stage 2
Study design
The investigators will conduct a mixed methods study to determine anticipatory acceptability of a co-designed protocol using the Theoretical Framework of Acceptability questionnaire informed by the Theoretical Framework of Acceptability (TFA).
Data to be collected
The investigators will develop an interview guide addressing the seven domains (affective attitude, burden, ethnicality, perceived effectiveness, intervention coherence, self-efficacy and opportunity costs) of the TFA to qualitatively assess acceptability of the co-designed protocol. The investigators will administer the TFA Questionnaire at the start of the interview to obtain a quantitative score of acceptability. Interviews will be on-line (each lasting 45 minutes long) using Microsoft Teams, digitally recorded and transcribed by a professional transcription company.
Patients and family (NHS and non-NHS participants)
The investigators will collect data including name, age, contact details, gender, ethnicity, and job status for patients, family taking part.
Healthcare staff (NHS participants)
The investigators will collect data including name, age, contact details, gender, ethnicity, professional role, location of job, length of time in current position, and duration of intensive care career to date for healthcare staff taking part.
Data analysis
Qualitative analysis:
The investigators will use The Framework Method using the TFA concepts as the backbone of the framework. The investigators will dual-code transcripts coding data within the domains of the TFA. The investigators will group and mark codes from the transcripts with one or more short descriptors to organise the raw data. The codes will then be grouped, summarised and categorised according to their meaning, similarities and differences. The investigators will use the data management tool NVivo to support the coding and the analysis of the qualitative data. The investigators will use the consolidated criteria for reporting qualitative studies (COREQ) validated checklist to ensure transparent reporting, rigor and credibility.
Quantitative analysis The investigators will analyse the scores from the TFA questionnaire computing the total mean score of the 7 domains as a single acceptability score.
Following analysis of both qualitative and quantitative datasets, the investigators will integrate both using established methodological triangulation to provide a mixed methods interpretation. This involves comparing both qualitative and quantitative datasets to confirm areas of convergence and divergence in the two datasets. Triangulation will help to increase validity of the research findings and explain research biases. The investigators will integrate findings using a convergence-coding matrix.
Stage 1: mechanically ventilated adult ICU patients Stage 2: Healthcare professionals (doctors, nurses and pharmacists) with experience caring for ECMO patients. ECMO survivors who have recovered and discharged from hospital, and their family.
Stage 1 (multi-centre observational study):
Inclusion Criteria:
Exclusion Criteria:
Stage 2 (mixed methods study):
Inclusion Criteria:
Exclusion Criteria:
Mechanically ventilated adult ICU patients who received ECMO organ support
Other: Not an intervention study
Doctors, nurses and pharmacists who look after ECMO patients
Other: Not an intervention study
Mechanically ventilated adult ICU patients who did not receive ECMO organ support
Other: Not an intervention study
ECMO survivors who have recovered and discharged from hospital. Family of ECMO survivors.
Other: Not an intervention study
This is not an intervention study
ICU mortality
Death whilst in ICU
Time frame: Through study completion, an average of 1 year
ICU length of stay
Length of stay in tertiary ICU
Time frame: Through study completion, an average of 1 year
Delirium
Occurrence of delirium during study period
Time frame: Through study completion, an average of 1 year
Plan to share: Yes — The King's Open Research Data System (KORDS) at King's College London will be used as a data repository, which will provide long-term storage and access for anonymised data and study protocol at project-end and to support publications. KORDS uses the Figshare data repository platform, providing a simple, self-deposit way for researchers to upload and share their data, and a publicly accessible showcase of datasets from King's research. It supports Open Research, enabling researchers to make datasets discoverable, accessible and citeable. All datasets have a DOI and a structured metadata record so that they can be shared and cited when re-used. Depositing meets the policy requirements of funders for data retention and sharing, and the requirements of many publishers for access to datasets supporting publications.
Supporting information: Study protocol
Time frame: The data will be made available following publication of research findings in peer-reviewed manuscripts and presentation at international conferences.
Access criteria: Institution access will be needed to access any data. This includes permission to access the specific university and hospital servers. Potential users will require tools including Microsoft Excel and Microsoft Word to access and use the data, which are widely adopted in many institutions and sustainable. The data will be shared via the University repository KORDS but it will not be openly accessible. Requests for access to the data will be handled directly by the research team in line with local policies.
Data sharing details ↗ · www.kcl.ac.uk
Started Nov 2025 (actual). Primary completion is estimated for Aug 2027, 21 months after the start.
Of 228 non-industry observational studies under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 21 months is below that.
Counting every sponsor, half of 234 studies reached it within 24 months; a quarter within 12 and three quarters within 49.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Respiratory Distress Syndrome →
Guy's and St Thomas' NHS Foundation Trust →